Stocks CNBC 66d ago

Eli Lilly says obesity pill helps maintain weight loss after patients switch from Wegovy, Zepbound

Market Intelligence Analysis

AI-Powered
Why This Matters

Eli Lilly's obesity pill, orforglipron, has shown to maintain weight loss in patients who switched from other treatments like Wegovy and Zepbound, and the company has filed for FDA approval.

Market Impact

Market impact analysis based on bullish sentiment with 76% confidence.

Sentiment
Bullish
AI Confidence
76%

Article Context

Note: This is a brief excerpt for context. Click below to read the full article on the original source.

Eli Lilly also said it has filed for Food and Drug Administration approval of the daily GLP-1 pill, called orforglipron, for obesity.

Continue Reading
Full article on CNBC
Read Full Article

Related Articles

Stocks 20h ago

The 18 highest-paying college majors 5 years after graduation

Engineering majors tend to earn high salaries, exceeding $75,000 within five years of graduation, indicating …
Stocks 21h ago

34-year-old spent $16K to start a side hustle, built it 20 minutes …

A 34-year-old entrepreneur, Julia Holden, started her business Sleepy Hat with an initial investment of …
Stocks 22h ago

Under mounting toy pressures, Hasbro has a secret sauce that Mattel hasn't …

Hasbro's Wizards of the Coast division has been a key factor in the company's success, …
Stocks 1h ago

India delays Washington trade visit as U.S. tariff policy shifts, source tells …

India has delayed a trade visit to the U.S. due to the U.S.'s shift in …
Stocks 18h ago

Airlines waive change fees ahead of another monster winter storm

Major US airlines have waived change and cancellation fees in anticipation of a severe winter …
Stocks 19h ago

Trump to hike global tariffs to 15% from 10%, 'effective immediately'

US President Trump has announced a 50% increase in global tariffs to 15% effective immediately, …
Original article published by CNBC on December 18, 2025.
Analysis and insights provided by AnalystMarkets AI.